CD34 and uterine corpus sarcoma: The presence of CD34 and/or S100 positivity on immunohistochemistry in a uterine sarcoma of the lower uterine segment or the cervix should trigger further NTRK testing, as an NTRK fusion may provide targeted therapeutic options with a potential positive impact on patient survival.